Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better InvestmentSeeking Alpha • 06/06/25
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCOCNBC • 06/03/25
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug raceMarket Watch • 06/02/25
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor TypesBusiness Wire • 06/02/25
Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?Zacks Investment Research • 05/29/25
Bristol-Myers Squibb Company (BMY) Bernstein 41st Annual Strategic Decisions Conference (Transcript)Seeking Alpha • 05/28/25
Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To BuySeeking Alpha • 05/28/25
Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceBusiness Wire • 05/28/25
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor IndicationsBusiness Wire • 05/28/25
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research PipelineBusiness Wire • 05/22/25
Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions ConferenceBusiness Wire • 05/21/25
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?Zacks Investment Research • 05/19/25